West Pharmaceutical Services Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Dow Jones
17 Jan

DJ West Pharmaceutical Services Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of West Pharmaceutical Services Inc. (WST) rose 2.49% to $337.20 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.21% to 5,937.34 and Dow Jones Industrial Average falling 0.16% to 43,153.13.

This was the stock's second consecutive day of gains.

West Pharmaceutical Services Inc. closed 18.49% short of its 52-week high of $413.70, which the company achieved on February 7th.

The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Abbott Laboratories $(ABT)$ rose 2.53% to $113.91, Becton Dickinson & Co. $(BDX)$ rose 1.60% to $236.30, and Baxter International Inc. $(BAX)$ rose 2.45% to $30.95.

Trading volume (384,881) remained 139,602 below its 50-day average volume of 524,483.

Data source: Dow Jones Market Data, FactSet. Data compiled January 16, 2025.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

January 16, 2025 17:04 ET (22:04 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10